5-Amino-1MQ
Small-molecule NNMT inhibitor discussed in preclinical metabolic/obesity contexts; human evidence is not established in the open literature.
Evidence last reviewed: 04 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence for 5-Amino-1MQ is primarily preclinical, showing potential benefits in animal models related to obesity and metabolic regulation. However, the absence of human clinical trials limits its applicability and understanding of safety and effectiveness.
NNMT inhibition & metabolic regulation (preclinical review)Preclinical models; no human clinical trials identified · Review (preclinical; target-focused)Low
A 2024 review summarizes NNMT as a therapeutic target for metabolic syndrome, noting preclinical evidence for NNMT inhibitors including 5-amino-1MQ; no human clinical trials have been published as of 2025.
Diet-induced obesity / metabolic endpoints (preclinical)Animal/preclinical models (as summarized in target-focused literature) · Preclinical summary (target-focused article)Low
Literature discussing NNMT inhibition reports preclinical benefits on obesity-related outcomes; statements about 5-amino-1MQ efficacy are not equivalent to replicated human trials.